In early December of the same year, the construction of a plant was started in the Special Economic Zone (SEZ) of Togliatti. The dynamic construction pace allowed to launch the production site in 2019. Simultaneously with the plant construction, the company carried out laboratory developments of property biosimilar products. The first drug developed and manufactured by Mabscale, LLC is currently undergoing clinical trials; several products are at the stage of preclinical trials; some drugs are at the stage of in-house development with the involvement of leading institutions and companies in the global biopharmaceutical market. Advantages
| Website | http://www.mabscale.ru |
| Revenue | $16.4 million |
| Employees | View employees |
| Phone | +7 848 267-89-90 |
| Industry | Pharmaceuticals, Healthcare |
| SIC | SIC Code 28 Companies, SIC Code 283 Companies |
| NAICS | NAICS Code 325 Companies, NAICS Code 32 Companies |
Looking for a particular Mabscale employee's phone or email?
Mabscale Questions
The Mabscale annual revenue was $16.4 million in 2026.
The NAICS codes for Mabscale are [325, 32].
The SIC codes for Mabscale are [28, 283].
